GEMINA LABS LTD Market Cap ($1.53 Million)
Market Cap & Net Worth: GEMINA LABS LTD (8I7)
GEMINA LABS LTD market cap. GEMINA LABS LTD (F:8I7) has a market capitalization of $1.53 Million (€1.31 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #30322 globally and #2632 in its home market, demonstrating a -16.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GEMINA LABS LTD's stock price €0.02 by its total outstanding shares 76570907 (76.57 Million). Also see how efficiently does GEMINA LABS LTD generate cash for how efficiently the company converts equity into cash flow.
GEMINA LABS LTD Market Cap History (2021–2026)
GEMINA LABS LTD market cap history from 2021 to 2026. Data shows change from $23.99 Million to $1.61 Million (-45.99% CAGR). Check GEMINA LABS LTD (8I7) share price today for real-time trading data and today's change.
GEMINA LABS LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GEMINA LABS LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 8I7 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8I7 by Market Capitalization
Companies near GEMINA LABS LTD in the global market cap rankings as of November 3, 2026. Also see 8I7 total assets for a full breakdown of the balance sheet.
Key companies related to GEMINA LABS LTD by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of GEMINA LABS LTD (2021–2026)
Market capitalization of GEMINA LABS LTD from 2021 to today. Between 2021 and today, GEMINA LABS LTD's market cap moved from $23.99 Million to $ 1.61 Million, with a yearly change of -45.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.61 Million | -67.86% |
| 2025 | €5.01 Million | -88.19% |
| 2024 | €42.43 Million | +40.24% |
| 2023 | €30.26 Million | -5.06% |
| 2022 | €31.87 Million | +32.84% |
| 2021 | €23.99 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of GEMINA LABS LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.53 Million USD |
| MoneyControl | $1.53 Million USD |
| MarketWatch | $1.53 Million USD |
| marketcap.company | $1.53 Million USD |
| Reuters | $1.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GEMINA LABS LTD
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more